News
![]()
Vaccinogen believes this novel asset, the B-cell collection, and potentially materials developed during the 8701 trial and predecessor company efforts, represent a valuable asset that can generate significant upfront fees, development milestones and royalties via collaborations and licensing activities that will complement the OncoVAX® investment opportunity.
![]()
Michael G. Hanna, Jr., Ph.D. discusses OncoVAX® at the Cancer Immunotherapy: A Long-Awaited Reality Conference in NY.

Publications
Human Vaccines 2006
Active Specific Immunotherapy with Autologous Tumor Cell Vaccines
Learn more >>
Cancer Vaccine Space
Vaccinogen is uniquely positioned within the cancer vaccine space
Learn more >>

